Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 8Classical hematology 2Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 94fludarabine phosphate 87Busulfan 64Cyclosporine 57Epoetin Alfa 55Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53fludarabine 45Antilymphocyte Serum 43Filgrastim 41Cytarabine 41Melphalan 40Tacrolimus 39Darbepoetin alfa 39Methotrexate 34Radiotherapy 33Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23apixaban 22Methylprednisolone 22Rivaroxaban 21Etoposide 21Thiotepa 17Dalteparin 17eltrombopag 16ferric carboxymaltose 14epoetin beta 14Daunorubicin 14Azacitidine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
cedazuridine × Classical hematology × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡